Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Tennessee: - Tennessee Oncology-Chattanooga ( Site 0045) — Chattanooga, Tennessee
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0031) — Nashville, Tennessee
Phase 3 Recruiting Industry
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT07007312
Sites in Tennessee: - Baptist Clinical Research Institute — Memphis, Tennessee
- Tennessee Oncology — Nashville, Tennessee
- TriStar Centennial Medical Center — Nashville, Tennessee
Phase 2, Phase 3 Recruiting Industry
Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at es…
Sponsor: Taiho Oncology, Inc.
NCT ID: NCT04256317
Sites in Tennessee: - Vanderbilt University Medical Center — Nashville, Tennessee
Phase 3 Recruiting Industry
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Sites in Tennessee: - Sarah Cannon Research Institute SCRI — Nashville, Tennessee
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in Tennessee: - Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
- Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
Phase 2 Recruiting Network
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (ref…
Sponsor: Children's Oncology Group
NCT ID: NCT02981628
Sites in Tennessee: - T C Thompson Children's Hospital — Chattanooga, Tennessee
- East Tennessee Childrens Hospital — Knoxville, Tennessee
- Saint Jude Children's Research Hospital — Memphis, Tennessee
- The Children's Hospital at TriStar Centennial — Nashville, Tennessee
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 2 Recruiting NIH
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in Tennessee: - East Tennessee Childrens Hospital — Knoxville, Tennessee
- The Children's Hospital at TriStar Centennial — Nashville, Tennessee
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Tennessee: - East Tennessee Childrens Hospital — Knoxville, Tennessee
- Saint Jude Children's Research Hospital — Memphis, Tennessee
- The Children's Hospital at TriStar Centennial — Nashville, Tennessee
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 2 Recruiting Industry
This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \[μg/kg/day\]), used in combination with venetoclax and azacitidine, to determine the dose for Part …
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06456463
Sites in Tennessee: - Sarah Cannon, the Cancer Institute of HCA Healthcare — Nashville, Tennessee
- Tennessee Oncology — Nashville, Tennessee
Phase 2 Recruiting NIH
This phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen), for the treatment of patients with core binding factor acute myeloid leukemia…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06917911
Sites in Tennessee: - Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
- Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
Phase 2 Recruiting Industry
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-…
Sponsor: Genmab
NCT ID: NCT05283720
Sites in Tennessee: - Thompson Cancer Survival Ctr /ID# 242150 — Knoxville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate t…
Sponsor: Cellectis S.A.
NCT ID: NCT04150497
Sites in Tennessee: - Sarah Cannon - HCA Research Institute — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid mali…
Sponsor: AVM Biotechnology Inc
NCT ID: NCT04329728
Sites in Tennessee: - Baptist Clinical Research Institute — Memphis, Tennessee
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
Sponsor: Vironexis Biotherapeutics Inc.
NCT ID: NCT06533579
Sites in Tennessee: - TriStar BMT — Nashville, Tennessee
Phase 2 Recruiting Industry
This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancies. Orca-T is an …
Sponsor: Orca Biosystems, Inc.
NCT ID: NCT07216443
Sites in Tennessee: - Vanderbilt University, Ingram Cancer Center — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This study is testing Allo-QuadCAR01-T, a new off-the-shelf CAR-T therapy for people with hard-to-treat B-cell cancers. Unlike current CAR-T treatments that use a patient's own cells, this therapy uses donor cells that are ready to use, wh…
Sponsor: AvenCell Therapeutics, Inc.
NCT ID: NCT07284433
Sites in Tennessee: - Sarah Cannon Research Institute — Nashville, Tennessee
Phase 2 Recruiting Academic/Other
This will be a randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on skeletal muscle quality and VO2max in AYA HCT survivors. The primary outcome is the change in mus…
Sponsor: Children's Hospital of Philadelphia
NCT ID: NCT05194397
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Phase 1, Phase 2 Recruiting Academic/Other
This is a phase I/II clinical trial assessing the tolerability and efficacy of CM4620 in children and young adults with acute pancreatitis caused by asparaginase. The tolerability of CM4620 when given to patients receiving frontline chemot…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT04195347
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Phase 2 Recruiting Academic/Other
CAR19PK is a research study evaluating the use of lymphodepleting chemotherapy and chimeric antigen receptor (CAR) T cell therapy, a type of cellular therapy, for the treatment of refractory and/or relapsed leukemia. For this type of thera…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT06847269
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Phase 1 Recruiting Industry
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT05735184
Sites in Tennessee: - TriStar Bone Marrow Transplant — Nashville, Tennessee
Phase 1 Recruiting Industry
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose c…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT06001788
Sites in Tennessee: - Vanderbilt University Medical Center — Nashville, Tennessee
Phase 1 Recruiting Academic/Other
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT02074839
Sites in Tennessee: - Sarah Cannon Research Institute — Nashville, Tennessee
Phase 1 Recruiting Network
This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic…
Sponsor: Children's Oncology Group
NCT ID: NCT06247787
Sites in Tennessee: - Saint Jude Children's Research Hospital — Memphis, Tennessee
Phase 1 Recruiting Industry
Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Participants aged ≥ 12 years are planned to be enrolled. CBX-250 will initially be investigat…
Sponsor: Crossbow Therapeutics, Inc.
NCT ID: NCT06994676
Sites in Tennessee: - Sarah Cannon Cancer Institute — Nashville, Tennessee
- Vanderbilt University Medical Center — Nashville, Tennessee
Phase 1 Recruiting Academic/Other
This is a Phase 1, open label, multicenter, dose finding study with dose expansion intended to evaluate the safety and tolerability of talazoparib in combination with conventional chemotherapy. Preliminary estimates of efficacy will be obt…
Sponsor: Norman J. Lacayo
NCT ID: NCT05101551
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee